Fig 1.
Cumulative incidence of grade II–IV and III–IV acute graft-versus-host disease (aGVHD) by day 100 in the post-transplant cyclophosphamide (PTCy) group (solid line) compared with the conventional group (dotted line), all patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.